Centanafadine, a new ADHD stimulant, goes into Schedule III, not Schedule II
The Drug Enforcement Administration has placed centanafadine, a new ADHD medicine, in Schedule III[1]. The rule took effect on October 30, 2026[1]. FDA approved the drug, sold as Simtriyo, on July 24, 2026, for adults and for children 6 and older who weigh at least 20 kg[1].
Why Schedule III and not II. Centanafadine is a stimulant: it blocks the reuptake of norepinephrine, dopamine and serotonin[1]. The familiar ADHD stimulants, amphetamine and methylphenidate, are Schedule II. FDA and DEA both found centanafadine's abuse potential lower than that of Schedule II stimulants[1]. In the human abuse study, amphetamine scored high on drug liking, while centanafadine moved toward disliking as the dose went up[1].
It has no street presence. DEA's forensic lab data show no law-enforcement encounters of it in the United States[1].
How it was scheduled
This is the expedited path Congress set for newly approved medicines. The rule is an interim final rule, effective at once, with comments taken afterwards[1]. Comments and hearing requests are due by November 30, 2026[1], under Docket No. DEA-1743[1].
Comments
Sign in to join the conversation.
No comments yet.